Episode
Space Race Acquisition
- Podcast
- Tech Brew Ride Home
- Published
- Apr 14, 2026
- Duration seconds
- 1241
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/tech-brew-ride-home-331078/episodes/space-race-acquisition/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/tech-brew-ride-home-331078/space-race-acquisition.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Amazon's dropping $10.8 billion on Globalstar to beef up its Leo satellite network and challenge Starlink — and Apple's along for the ride. Plus, federal charges for the Sam Altman attacker, OpenAI acqui-hires a fintech startup, Google declares war on back button hijacking, data labeling startups are printing money, and Missouri voters revolt over a data center. Amazon agrees to acquire satellite operator Globalstar for $10.8B to expand Leo satellite network; Amazon and Apple say Leo will power some iPhone and Watch services (Amazon) Amazon to Acquire Globalstar in Satellite Cellular-Connection Push (WSJ) US DOJ charges Daniel Moreno-Gama, accused of throwing a Molotov cocktail at Sam Altman's home, with attempted murder and arson (CNN) Man who attacked OpenAI CEO's home had list of other AI executives (NYT) OpenAI acquires personal finance startup Hiro Finance (TechCrunch) Google designates "back button hijacking" as malicious, sites could be demoted in Search from June 15 (9to5Google) Data labeling startup Handshake's gross annualized revenue hits ~$1B; Mercor also at $1B+ pace (The Information) Voters in Festus, Missouri oust all four incumbent council members days after council approved a $6B data center (Politico) Learn more at liquid.trade/techbrew. Disclaimer: ● Initial 3 week subscription and 4 weeks of medication from $79 plus tax and $179 per month plus tax for 12 week subscription thereafter. Final pricing depends on program selection.● Noom GLP-1Rx Program involves healthy diet, exercise and support. Individual results vary. Meds & personalization based on clinical need. Not reviewed by FDA for safety, efficacy, or quality. No affiliation with Novo Nordisk Inc., the only US source of FDA-approved semaglutide. Not available in all 50 US states● Based on an a…